BCK Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

BCK Capital Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-22,000	Closed	-$900K	–	83
2024 Q2	$900K	Hold	22,000	–	–	0.58%	41
2024 Q1	$930K	Hold	22,000	–	–	0.63%	36
2023 Q4	$933K	Buy	+22,000	New	+$632K	0.91%	34

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

BCK Capital Management's CERE Position: Q3 2024 in Review

BCK Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 22,000 shares — an estimated $900K sold.

BCK Capital Management first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $933K in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

BCK Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
BCK Capital Management sold 22,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $900K.
BCK Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
BCK Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $933K in Q4 2023.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on BCK Capital Management's 13F filing for Q3 2024, filed 7 Nov 2024.